Name | Value |
---|---|
Revenues | 11.5M |
Cost of Revenue | 7.2M |
Gross Profit | 4.3M |
Operating Expense | 11.2M |
Operating I/L | -6.9M |
Other Income/Expense | -1.2M |
Interest Income | 0.0M |
Pretax | -8.1M |
Income Tax Expense | 0.0M |
Net Income/Loss | -8.1M |
Aziyo Biologics, Inc. is a regenerative medicine company specializing in developing products for the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. Its offerings include CanGaroo, a product designed to reduce infection risk post-surgical implantation of electronic devices, as well as cardiovascular products like ProxiCor, Tyke, and VasCure for tissue repairs and peripheral vasculature reconstruction. The company also provides human tissue-derived bone allografts such as Fiber VBM, ViBone, and OsteGro V, along with SimpliDerm for integumental tissue repair. Additionally, it offers contract manufacturing services for various products to corporate customers.